A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
Male
Models, Molecular
Protein-Arginine N-Methyltransferases
0303 health sciences
Cell Death
Dose-Response Relationship, Drug
Molecular Structure
Antineoplastic Agents
Mice, Inbred Strains
Lymphoma, Mantle-Cell
Crystallography, X-Ray
Isoquinolines
Methylation
Xenograft Model Antitumor Assays
3. Good health
Inhibitory Concentration 50
03 medical and health sciences
Pyrimidines
Cell Line, Tumor
Animals
Humans
Cell Proliferation
Protein Binding
DOI:
10.1038/nchembio.1810
Publication Date:
2015-04-27T15:26:20Z
AUTHORS (30)
ABSTRACT
Protein arginine methyltransferase-5 (PRMT5) is reported to have a role in diverse cellular processes, including tumorigenesis, and its overexpression is observed in cell lines and primary patient samples derived from lymphomas, particularly mantle cell lymphoma (MCL). Here we describe the identification and characterization of a potent and selective inhibitor of PRMT5 with antiproliferative effects in both in vitro and in vivo models of MCL. EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 enzymatic activity in biochemical assays with a half-maximal inhibitory concentration (IC50) of 22 nM and broad selectivity against a panel of other histone methyltransferases. Treatment of MCL cell lines with EPZ015666 led to inhibition of SmD3 methylation and cell death, with IC50 values in the nanomolar range. Oral dosing with EPZ015666 demonstrated dose-dependent antitumor activity in multiple MCL xenograft models. EPZ015666 represents a validated chemical probe for further study of PRMT5 biology and arginine methylation in cancer and other diseases.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (51)
CITATIONS (479)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....